Cargando…
Pharmacogenetic variation of SLC47A1 gene and metformin response in type2 diabetes patients
Type 2 diabetes mellitus is a worldwide epidemic disorder with considerable health and economic consequences. Metformin is one of the most commonly prescribed oral antidiabetic drugs. Pharmacogenetic studies showed that variants in genes related to the pharmacokinetics of metformin were associated w...
Autores principales: | Mousavi, Saeedeh, Kohan, Leila, Yavarian, Majid, Habib, Asadollah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shiraz University
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534524/ https://www.ncbi.nlm.nih.gov/pubmed/28775995 |
Ejemplares similares
-
Association of SLC22A1, SLC22A2, SLC47A1, and SLC47A2 Polymorphisms with Metformin Efficacy in Type 2 Diabetic Patients
por: Chen, Peixian, et al.
Publicado: (2022) -
Genomic editing of metformin efficacy-associated genetic variants in SLC47A1 does not alter SLC47A1 expression
por: Kalamajski, Sebastian, et al.
Publicado: (2021) -
Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer
por: Ingle, James N
Publicado: (2008) -
Positive perception of pharmacogenetic testing for psychotropic medications
por: Lanktree, Matthew B, et al.
Publicado: (2014) -
The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients
por: Xiao, Di, et al.
Publicado: (2016)